GRAIL, Inc. (GRAL)
NASDAQ · Healthcare
As of Jul 20, 2026
Price history
Key statistics
- Market cap
- $3.09B
- P/E ratio
- —
- EPS
- —
- Volume
- 442,265
- 52-week high
- —
- 52-week low
- —
- Open
- $72.35
- Day high
- $72.57
- Day low
- $68.64
Financial highlights
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| 2025 | $147.17M | -$408.35M | -$11.11 |
| 2024 | $125.6M | -$2.03B | -$63.54 |
| 2023 | $93.11M | -$1.47B | -$47.21 |
About GRAIL, Inc.
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, its precision oncology portfolio consists of n RUO-targeted methylation-based platform that enables applications for disease prognostication, risk stratification, minimal residual disease detection, and recurrence and relapse monitoring. The company was incorporated in 2015 and is headquartered in Menlo Park, California.
- CEO
- Robert Ragusa
- Employees
- 910
- Country
- US
- IPO date
- Jun 12, 2024
Similar stocks
Other Healthcare companies
Frequently asked questions
- What is GRAIL, Inc.'s stock price today?
- GRAL is trading at $68.91 as of Jul 20, 2026.
- What is GRAIL, Inc.'s market cap?
- GRAIL, Inc. (GRAL) has a market capitalization of $3.09B.
- Does GRAIL, Inc. pay a dividend?
- GRAIL, Inc. did not pay a dividend in its most recent reported fiscal year.
- What sector is GRAIL, Inc. in?
- GRAIL, Inc. operates in the Healthcare sector.